IGEN Intl granted early termination of the waiting period under Hart-Scott-Rodino
(IGEN) 57.72 +0.12: FTC grants early termination of the waiting period under Hart-Scott-Rodino
with respect to the previously announced transaction between IGEN and Roche Holding Ltd.
IGEN Announces Early Termination of the
Waiting Period Under Hart-Scott-Rodino Act
Monday September 29, 4:40 pm ET
GAITHERSBURG, Md., Sept. 29 /PRNewswire-FirstCall/ -- IGEN International, Inc.
(Nasdaq: IGEN - News) announced today that the Federal Trade Commission has
granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976 with respect to the previously announced transaction
between IGEN and Roche Holding Ltd. The expiration or termination of this waiting
period under the Hart-Scott-Rodino Act is one of the conditions to closing contained in
the merger agreement between the two companies.
More information about the
transaction with Roche may be
found in the registration statement
on Form S-4 that BioVeris
Corporation, a wholly owned
subsidiary of IGEN, filed with the
Securities and Exchange
Commission on September 26,
2003. This registration statement
contains a preliminary version of the
proxy statement/prospectus that,
once final, will be mailed to IGEN
stockholders in connection with a
special meeting of stockholders to
vote on the proposed merger and
any other matters that might be
presented at the meeting. The proxy
statement/prospectus will be mailed
after the SEC declares the registration statement effective.
BioVeris, which was previously called IGEN Integrated Healthcare, LLC, is the company
that was referred to as "Newco" in the definitive agreements relating to the transaction
with Roche. As previously disclosed, if the transaction with Roche is completed, IGEN
stockholders will be entitled to receive $47.25 in cash, without interest, and one share
of BioVeris common stock for each share of IGEN common stock they own.
CC |
